Kentucky Meridia Attorney: FDA Issues Warning About Meridia Drug
Bahe Cook Cantley & Jones Meridia lawyer Larry Jones says, "The federal Food & Drug Administration has notified healthcare professionals and patients that it is reviewing preliminary data from a recent study suggesting that patients using sibutramine have a higher number of cardiovascular events (heart attack, stroke, resuscitated cardiac arrest, or death) than patients using a placebo (sugar pill)." According to Jones, "Sibutramine is marketed as Meridia in the United States. The Meridia drug was approved by the FDA in 1997 for the management of obesity, including weight loss and maintenance of weight loss, in conjunction with a reduced calorie diet."
"While the FDA's analysis is ongoing and the FDA is making no conclusions about the preliminary findings at this time, the FDA's Meridia findings highlight the importance of avoiding the use of sibutramine in patients with a history of coronary artery disease (heart disease), congestive heart failure (CHF), arrhythmias, or stroke, as recommended in the current sibutramine labeling."
For more information about the rights of those who were injured or killed while using Meridia, contact Larry Jones directly at (502) 587-2002 or by email: click here to email Larry.
